

Learning chemical sensitivity reveals mechanisms of cellular response

William Connell^{1,2,3}, Kristle Garcia^{3,4,5,6}, Hani Goodarzi^{3,4,5,6}, Michael J. Keiser^{1,2,3}

1. Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA, USA
2. Institute for Neurodegenerative Diseases, University of California, San Francisco, San Francisco, CA, USA
3. Bakar Computational Health Sciences Institute, University of California, San Francisco, San Francisco, CA, USA
4. Department of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, CA, USA
5. Department of Urology, University of California, San Francisco, San Francisco, CA, USA
6. Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA

Correspondence: keiser@keiserlab.org

Abstract

Chemical probes interrogate disease mechanisms at the molecular level by linking genetic changes to observable traits. However, comprehensive chemical screens in diverse biological models are impractical. To address this challenge, we developed ChemProbe, a model that predicts cellular sensitivity to hundreds of molecular probes and drugs by learning to combine transcriptomes and chemical structures. Using ChemProbe, we inferred the chemical sensitivity of cancer cell lines and tumor samples and analyzed how the model makes predictions. We retrospectively evaluated drug response predictions for precision breast cancer treatment and prospectively validated chemical sensitivity predictions in new cellular models, including a genetically modified cell line. Our model interpretation analysis identified transcriptome features reflecting compound targets and protein network modules, identifying genes that drive ferroptosis. ChemProbe is an interpretable *in silico* screening tool that allows researchers to measure cellular response to diverse compounds, facilitating research into molecular mechanisms of chemical sensitivity.

Introduction

Chemical probes are highly potent small molecules that selectively target known mechanism-of-action proteins¹. These tools are crucial for understanding the role of specific proteins in biological processes and diseases, and have been instrumental in investigating a range of functions such as those related to the cell cytoskeleton, immunosuppression, mTOR signaling, protein kinase dynamics, and have often served as the starting point for drug development¹⁻³. In addition to their primary use as therapeutic agents, drugs can serve as chemical probes in complex diseases like cancer. Addressing cancer heterogeneity necessitates precision clinical treatment strategies and research into the mechanisms that control disease resistance and sensitivity^{4,5}. By improving our understanding of gene expression patterns contributing to variance in drug response, we can develop better solutions for cancer patients exploiting specific tumor vulnerabilities.

Ideally, we could test large libraries of chemicals on disease models, engineered cell lines, and patient samples to probe disease mechanisms. However, screening biological samples against a large library of chemical probes is resource-prohibitive. To overcome this problem, a

variety of traditional machine learning methods have been applied to predict drug response, including support vector machines (SVMs), random forests (RFs), and multi-layer perceptrons (MLPs)⁶. Early approaches often relied on a single cellular feature set, such as mutation status or gene expression profile⁷. However, significant improvements have been achieved by incorporating multimodal information, such as chemical structure and pharmacological features^{8,9}. These advancements have demonstrated the value of integrating diverse types of data to enhance drug response prediction.

Deep learning has become a way to effectively represent and integrate diverse feature sets. These methods commonly employ separate feature encoders that learn rich representations prior to integration^{10,11}. In one example, variational auto-encoders (VAEs) can also leverage pretraining for transfer learning^{12–15}. More broadly, neural networks are adaptable to novel inputs, such as graph representations for chemical structures^{16–18} and their composability provides exciting opportunities for feature integration such as cross-attention^{18,19}.

Interpreting the computational structure of predictive models themselves can inform on the underlying biology of compound response. On one hand, ensemble models offer confidence scores, and direct interpretation of model coefficients (e.g., attention matrices) reveals feature relationships^{19–22}. Gradient-based attribution methods can also help identify features driving a particular prediction¹⁵. On the other hand, integrating biological priors into neural networks effectively reduces the feature space and incorporates interpretable features, such as gene ontologies and pathway annotations^{23–25}. By imposing constraints through priors, learning operates in the context of existing biological knowledge. However, this approach can limit a model's capacity to learn novel gene combinations and systems mechanisms that are not well understood.

We developed a deep learning model that predicts the sensitivity of new cellular samples to a panel of chemicals along with a framework for understanding the gene features implicated in the response. ChemProbe learns to combine cellular transcriptomes and chemical structures to predict sensitivity. The model can be applied to new biological samples and leverages interpretable learned gene features relevant to known compound mechanisms. ChemProbe accurately models chemical response without biological priors, enabling *in silico* chemical screening of biological models and mechanistic interpretation of learned gene dependencies.

Results

Conditional modeling enhances cellular drug sensitivity prediction

We hypothesized that a deep neural network model could learn to combine gene expression with chemical structure to predict cellular sensitivity (Fig 1a). We leveraged publicly available datasets to match cancer cell line basal transcriptomes with a large-scale chemical screen. The Cancer Therapeutics Response Portal (CTRP) reports the viability of 842 cancer cell lines in response to 545 compounds and compound pairs across a range of concentrations²⁶. These compounds span cell circuitry targets, offering a nuanced view of cellular response to pathway perturbations across a broad range of cellular components. The Cancer Cell Line Encyclopedia (CCLE) provides basal transcriptomic characterizations of all 842 CTRP cell lines²⁷. We combined compound structures and concentrations from the CTRP with protein-coding gene transcriptomes from the CCLE to create a dataset of compound-cell line pairs consisting of approximately 5.8 million labeled examples (Methods).

We formulated the cellular drug sensitivity prediction task as a conditional model $y = f(x|n)$, where y is cellular viability, x is a matrix of standardized RNA abundance values, n is a matrix of chemical features, and f is parameterized by a neural network (Methods). Thus the model's prediction of cellular viability depends on a cell's transcriptomic profile in the context of a chemical structure and concentration. ChemProbe predicts viability by learning to use chemical features to modulate gene expression through linear transformations of internal gene expression representations (Fig 1b). This enables a logic akin to chemical substructures modulating gene products (proteins). We tested several ways to combine cellular features and chemical information within a single model, as assessed by the average maximum coefficient of determination (R^2). Accounting for comparable model sizes, we trained, validated, and hyperparameter-optimized different model architectures across five data folds stratified by cell line (five-fold cross-validation, Methods). We compared three methods of learned feature conditioning against a baseline feature concatenation approach²⁸. All conditioning approaches outperformed feature concatenation by a notable margin (Table 1). Among the conditioning models, scaling, shifting, and linearly modulating gene expression by chemical features performed similarly. A t-distributed stochastic neighbor embedding (t-SNE) decomposition of

learned parameters demonstrated that scaling and shifting operations encoded distinct chemical features (Fig 1c). Hierarchical clustering of scaling (γ) parameters grouped compounds by identity (Extended Data Fig 1a), whereas compound concentration correlated with the first principal component of shifting (β) parameters ($p=1.72e-55$, Extended Data Fig 1b). Thus the learned conditioning parameters interpretable reflected compound structure and concentration in the drug-response modeling task as an emergent property of model learning.

Cellular response commonly follows a sigmoidal relationship to drug concentration. To quantify whether compound dosage alone was driving drug sensitivity predictions, we performed a feature ablation experiment, wherein we purposefully removed crucial data from the model's training and compared it to the actual model. For the “straw model,”^{29,30} we replaced chemical fingerprints with unique but structurally uninformative and randomized numerical values. The “straw model” trained on ablated features failed catastrophically, underscoring the importance of compound structural features in the modeling task (Table 1)³⁰. Explicitly modeling chemical information as conditioning provides a valuable inductive bias for chemical sensitivity prediction and gives insights into the predictive mechanisms of the model. We hyperparameter optimized 5 FiLM models across cell-line stratified data folds and used this ensemble ($0.7173 \pm 0.0052 R^2$) of models in subsequent experiments (Methods).

ChemProbe predicts breast cancer patient response

We next asked whether learned transcriptional patterns would generalize to an *in vivo* cellular context. We measured how well ChemProbe, trained solely on cell line expression profiles, could predict drug response in clinical tumor samples. We used gene expression and patient drug response data from the I-SPY2 adaptive, randomized, phase II clinical trial of neoadjuvant therapies for early-stage breast cancer ([NCT01042379](https://clinicaltrials.gov/ct2/show/study/NCT01042379))^{31,32}. I-SPY2 assigned patients to treatment arms based on biomarkers such as hormone receptor status, human epidermal growth factor receptor-2 expression, and MammaPrint status. Absence of invasive cancer in the breast and regional lymph nodes at the time of surgery defined the endpoint of pathological complete response (pCR) (nonresponse, pCR=0; response, pCR=1).

The I-SPY2 dataset introduced a significant change in the input data modality and allowed us to assess the robustness of ChemProbe. Unlike the CCLE training data, which quantified gene expression through high-throughput RNA sequencing, I-SPY2 collected pre-

treatment patient gene expression by microarray. Microarrays have lower overall specificity and sensitivity and capture a smaller dynamic range of gene abundance³³. Neural networks often fail on “out of distribution” samples whose features (gene abundance values) come from different assays than their training data. To determine the extent to which the I-SPY2 data was outside ChemProbe’s training distribution, we compared dataset expression profiles across the top two principal components. A subset of the I-SPY2 data fell outside the training data distribution, consistent with the expectation that assay types introduce systematic measurement effects (Methods, Extended Data Fig 2a).

We assessed whether ChemProbe could retrospectively stratify I-SPY2 responders and non-responders despite these differences in datasets. The molecular characteristics of their tumors determined the drugs administered to the participants of the I-SPY2 trial. Five drugs from the I-SPY2 trial were in ChemProbe’s panel. We first compared the magnitudes of ChemProbe’s sensitivity predictions between responders and non-responders. For four out of five drugs, ChemProbe predicted lower scaled-AUC values for the responder group (Fig 2a). Next, we generated receiver operating characteristic (ROC) curves to compare the drug response predictions of I-SPY2 and ChemProbe with the trial outcomes. We used the treatment designations from I-SPY2 as a proxy for drug response prediction. ChemProbe’s area under the ROC curve for each drug ranged from 0.60 (paclitaxel and neratinib) to 0.73 (veliparib), with a macro-average auROC of 0.65 (Fig 2b).

To evaluate the clinical utility of ChemProbe, we used it to classify patients by treatment response: responders (+) and non-responders (-) (ChemProbe+/-). Since the model determines cellular viability by drug concentration, we established a decision threshold for detecting responders (Methods). ChemProbe+/- classification accuracy significantly outperformed I-SPY2 ($p < 5e-2$, Fig 2d). Although I-SPY2 predictions had a higher true positive rate (0.30, I-SPY2; 0.21, ChemProbe), ChemProbe+/- classifications massively reduced the false positive rate (0.70, I-SPY2; 0.37, ChemProbe) with relatively few false negatives (0.00, I-SPY2; 0.095, ChemProbe) (Extended Data Fig 2b,c). By correctly predicting a portion of patients with a low likelihood of drug response, ChemProbe+/- significantly increased the true negative rate of drug-response classification relative to I-SPY2, providing crucial information for clinical decision-making. Despite being trained only on isogenic cell lines, these results support ChemProbe’s use with heterogeneous tumors from clinical patient samples.

ChemProbe predicts cellular drug sensitivity

We conducted a prospective evaluation of ChemProbe's ability to differentiate drug sensitivity between two primary breast cancer cell lines, HCC1806-Par and MDA-MB-231-Par³⁴⁻³⁷. We compared the gene expression profiles of the two cell lines to their CCLE counterparts by analyzing the top two gene-expression principal components. Our analysis showed significant disparities in the gene expression patterns of the two cell lines compared to the training data, highlighting the challenges of maintaining consistency across cellular models (Extended Data Fig 3a). The observed differences, which make the prospective test more difficult but particularly informative, may be attributed to variations in cell culture protocols, reagents, and genetic drift commonly found between experimental settings³⁸.

We predicted sensitivity at 32 drug concentrations (1e-3 uM – 300 uM), fit log-logistic models, and determined 50% inhibitory concentration (IC50) values from each *in silico* dose-response curve (Fig 3a). ChemProbe predicted that HCC1806-Par would be more sensitive than MDA-MB-231-Par to 88.16% (201/228) of the compounds with fitted curves (Fig 3b). We focused on compounds with the largest differences in IC50 between the cell lines, selecting four compounds predicted to have strong IC50s against HCC1806-Par (neratinib, ceranib-2, CAY10618, and AZD7762) and two compounds with IC50s favoring MDA-MB-231-Par (ML162 and 1S,3R-RSL-3) (Fig 3c,d). *In vitro* prospective testing confirmed ChemProbe's predictions for all six compounds. Predicted differences in IC50s between the two cell lines significantly correlated with observed differences (Fig 4a-f; $p=0.035$, Fig 4g). We compared the relative potency of each compound at the median effective dose (ED50) between cell lines, finding significant differences in compound cellular viability as predicted (Table 2). Additionally, predicted IC50s correlated highly with measured IC50s for individual cell lines after correcting for an experimental outlier ($p=0.096$, Extended Data Fig 4a). These results were consistent with initial concentration range-finding experiments, where five out of six compounds had shown predicted differences in IC50s and relevant IC50s specific to individual lines (Extended Data Fig 4b,c). ChemProbe accurately predicted the sensitivities of independently obtained and characterized cell line samples, despite their transcriptomic profiles differing from the training dataset.

Gene expression attribution vectors pass interpretability soundness checks

To assess whether ChemProbe learned biologically relevant patterns, we investigated whether the model’s gene expression saliency reflected known compound pharmacology and network biology. Saliency mapping methods evaluate which gene features a model puts the most “weight” on when making its predictions and how these choices change for different cell lines or compounds. We experimentally characterized seven new cell line transcriptomes, including primary tissue models and metastatic derivatives^{39–41}. Using integrated gradients saliency mapping,⁴² we determined IC50 values for each compound-cell line pair with ChemProbe and computed its gene attribution vectors. However, we acknowledge that integrated gradient attribution vectors may correlate with input feature magnitudes, potentially undermining their usefulness in quantifying feature importances.⁴³ We used principal component analysis to determine the first two principal components of attribution vectors by cell line to check this. We found that attribution and transcriptome vectors correlated (Extended Data Fig 5a,c). To address this confounder, we normalized attribution vectors by line, which decreased cell-line-specific effects in the principal component analysis and decoupled the correlation between attribution and transcriptome vectors (Extended Data Fig 5b,c).

To ensure model interpretation accurately reflected learned feature transformations, we performed two tests (Methods)⁴³. The first test randomly initialized the model parameters and compared the outcomes with the true model’s attribution vectors. We trained the model using scrambled labels in the second test and compared its attribution vectors with the true model’s. We conducted these tests using both uncorrected (raw) and cell line-effect corrected (adjusted) attribution vectors. The raw attribution vectors were highly correlated with transcriptome profiles, random-model, and permuted-model attribution vectors, failing the tests of independence from learned parameters and the training data. However, the adjusted attribution vectors were not correlated with those derived from the control models, indicating that adjusted attribution vectors do not simply reflect data or parameter artifacts (Extended Data Fig 5c).

Learned transcriptomic features reflect compound pharmacology and network biology

Neural networks are notoriously difficult to interpret, but we hypothesized that ChemProbe’s highly attributed gene features may reflect causative mechanisms or correlative biomarkers of drug sensitivity. First, we investigated whether the model relied on similar gene

features for compounds with the same known protein targets. We created a control compound set (CCS) based on nominal target classes, each with at least two compounds successfully predicted in all seven cell lines. We applied K-means clustering to the CCS attribution vectors and computed the adjusted mutual information (AMI) between clusters and target class labels to determine whether transcriptomic attribution vector similarity corresponded to known compound mechanisms of action (MOA) (Fig 5a). We also examined the AMI between structural clusters and target classes, as chemical structure similarity alone may at times reflect target profile similarity, albeit imperfectly.⁴⁴

The attribution vector clusters AMI was significantly greater than that of structural clusters, a randomly initialized model, and a model trained on permuted labels (Fig 5b, Methods). Moreover, we found that compounds belonging to the same target class frequently had high nominal target attributions relative to other compounds, indicating that ChemProbe often made predictions based on the expression information of nominal targets (Fig 5c, Extended Data Fig 5d-k).

We next examined the network topology of nominal target classes using the STRING database of high-confidence protein-protein interactions⁴⁵ to interrogate biological relevance. We clustered attribution vectors, gathered target annotations within each cluster, and queried STRING for the respective target interactome (Methods). Target modules had significantly greater connectivity than modules generated from randomly sampled target protein sets or randomly sampled protein sets (Fig 5d). Finally, we tested whether attribution-defined target modules of action (ModOA) also showed protein interaction enrichment. On analysis, 50% of ModOA reflected significant network interaction enrichment and a variety of functional enrichments from gene ontologies, KEGG pathways, and Reactome pathways (Fig 5f). These findings suggest that highly attributed transcriptome features reflect systems biology and potential mechanisms of drug response.

Screening genetic dependencies for mechanisms of ferroptosis

We further hypothesized that ChemProbe's highly attributed gene features would relate to compound MOA. To test this, we used linear regression for differences in gene attribution between groups. This “differential attribution analysis” (DAA; see Methods) generates ranked gene lists, which we use as marker genes to arrange attribution clusters hierarchically (Fig 6a).

We noticed clusters 26 and 28 showed different prediction sensitivity to ferroptosis-inducing compounds (Fig 6b). Ferroptosis is a type of cell death implicated in multiple biological contexts, with therapeutic applications in cancer, immunity, development, and aging^{46,47}. These attribution clusters included compounds ML162 and 1S,3R-RSL-3, which had shown differential cellular sensitivity in the prospective *in vitro* experiments (Fig 4e-f). Additional compounds with ferroptosis-inducing mechanisms of action in these clusters included ML210, erastin, CIL56, and CIL70.

Digging down, we investigated the attribution vectors of ferroptosis-inducing compounds to assess the alignment of model interpretations with established ferroptosis biology. We observed a clear distinction in predicted sensitivity between two groups of cell lines exposed to the same compounds (Fig 6b). To further analyze this, we merged clusters 26 and 28 into a combined cluster representing ferroptosis-inducing compounds and applied DAA. Since multiple mechanisms induce ferroptosis, we queried differential attributions of multiple ferroptosis-associated genes, including GPX4, SCD, SLC7A11, FSP1, and LRP8⁴⁶. All ferroptosis-associated genes were within the most highly attributed in the ferroptosis-inducing compound cluster (Fig 6c). To verify that these results were not artifacts of the transcriptomes or relative gene expression differences, we also performed differential expression analysis (DEA) between MDA-MB-231-Par and HCC1806-Par. Besides GPX4, a key ferroptosis regulator, no ferroptosis-associated genes rose to significance ($p < 5e-2$, Extended Data Fig 6a).

Changes in compound sensitivity following gene knockout (KO) or overexpression can inform on mechanisms of gene-dependent protection or resistance. Accordingly, we assessed ChemProbe's utility for screening gene-dependent ferroptosis resistance *in silico*. Lipoprotein receptor LRP8 has recently been shown to act as a ferroptosis resistance factor by maintaining cellular selenium levels and appropriate translation of GPX4. Selenium uptake is reduced in LRP8 KO models, leading to ribosome stalling and early translation termination of GPX4, which sensitizes cells to ferroptosis⁴⁸. We tested if ChemProbe correctly predicted that a LRP8 KO cell line would have reduced sensitivity to ferroptosis-inducing compounds than a wild-type. Consistent with previous research, ChemProbe predicted LRP8 KO cells were more sensitive than wild-type to known ferroptosis-inducing compounds ML210, 1S,3R-RSL-3, ML162, and CIL56 (Fig 6d).

We noticed several correlations between cellular response and the expression of highly attributed genes for compounds that induce ferroptosis (Extended Data Fig 6b,c). We wondered if highly attributed genes played functional roles related to ferroptosis. We extracted the ten highest differentially-attributed genes and applied a functional enrichment analysis (Extended Data Fig 6d). We observed enrichment of terms related to lipid transport and fatty acid metabolic processes, pathways adjacent to lipid peroxidation and ferroptosis (Fig 6e). These results indicate that transcriptomic attributions align with ferroptosis biology, underscoring the potential of ChemProbe in screening genetic dependencies and identifying novel biological mechanisms.

Discussion

Using a conditional deep learning approach, ChemProbe evaluates cellular transcriptomic signatures against bioactive molecular structures to predict cellular responses to chemical perturbations. In experiments on cellular models and clinical tumor samples, this tool accurately predicts cellular viabilities prospectively. ChemProbe complements more clinically-oriented approaches with its ability to directly screen engineered cell lines and interrogate potential molecular mechanisms. Engineered cell lines, which possess specific genetic modifications or alterations, physically model disease conditions or the results of targeting pathways of interest. By leveraging ChemProbe, researchers can evaluate the sensitivity of known and newly engineered lines to a panel of chemical probes to assess how specific genetic modifications or alterations influence compound response.

Intriguingly, deep learning model interpretation reflects compound mechanisms of action (Fig 5). The differential attribution analysis (DAA) method we introduce surfaces potential gene patterns driving responses and new disease-gene relationships. In one example, we identified genes linked to ferroptosis resistance in an LRP8 knockout cell line. ChemProbe's calculations were not specific to this biology; it may find similar use in screens for resistance mechanisms and target discovery across diverse cellular models (Fig 6). In cancer research, the tool rapidly evaluates the influence of specific oncogenic mutations or alterations in tumor suppressor genes on chemical sensitivity. When applied to engineered cell lines representing different genetic backgrounds, ChemProbe can highlight vulnerabilities and potential mechanisms of drug resistance associated with particular genetic alterations.

Extending to clinical samples, ChemProbe becomes a tool for targeted therapy and precision medicine. We found that it predicts drug sensitivity in breast cancer patients across heterogeneous clinical tumor samples (Fig 2). Likewise, ChemProbe suggests which drugs may be ineffective for a given patient; if borne out in clinical studies, it or similar methods could meaningfully reduce therapeutic trial and error^{49,50}. The ability to expedite treatment at earlier disease stages and target cellular vulnerabilities would be particularly impactful for tumors whose resistance mechanisms rapidly evolve.

Nonetheless, several caveats merit mention. The experiments were constrained to a limited set of cell lines and compounds, and model interpretation reflects a limited set of biological factors. Without further study, gene features achieving high model attribution may reflect useful but obtuse patterns in the datasets rather than biological causality. Similarly, without a more diverse training set of chemical structures, the model may not be leveraging generalizable structural features. As always, deep learning model attribution methods are a moving target, so the potential compound mechanisms of action they reveal ultimately necessitate prospective biological testing^{51,52}.

ChemProbe screens cell lines against half a thousand chemical probes and drug-like compounds. However, expanding its predictions to a larger subset of chemical space would require collecting biological screening training data at a commensurate scale, which is currently impractical. Deep learning models like AlphaFold and ESM have leveraged self-supervised learning to extract emergent properties from extensive unlabeled protein sequence data^{53,54}. Similarly, integrating ChemProbe with pretrained cellular transcriptomic or small-molecule structure foundation models may be a means to expand into broader biological and chemical space.

When used to screen disease models, engineered cell lines, and clinical samples, ChemProbe is a powerful tool to assess how cells respond to various compounds. It supports exploring new therapeutic targets, suggests disease mechanisms, and can help researchers develop more precise and effective treatments. In this study, ChemProbe predicted drug sensitivities in multiple contexts, from cancer cells and tumor samples to data on breast cancer patient responses. Looking forward, we hope that ChemProbe's availability as an open-source tool will contribute to a range of research efforts in precision medicine and beyond.

Materials and Methods

Pharmacogenomic dataset

Drug sensitivity data was obtained from the Cancer Therapeutic Response Portal v1 and v2 (CTRP v1/2). These datasets comprise 864 cell line responses to 481 individual compounds and 64 compound pairs across a range of concentrations. Response phenotypes were quantified by cellular viability, a normalized measure characterizing complete cell killing to cell stasis (0-1) and cell growth (>1). We utilized predicted cellular viability derived from fitted dose-response curves of each experimental set, in which replicate cell line-compound experiments were fit with a log-logistic function and predicted cellular viability was derived at the original experimental concentrations (Seashore-Ludlow). Compound structure was represented as 512-bit Morgan fingerprints (radius = 2) converted by RDKit from SMILES provided by the CTRP. Experimental micromolar compound concentrations were concatenated with Morgan fingerprints, resulting in 513-length compound feature vectors. We matched CTRP cell lines with the Cancer Cell Line Encyclopedia (CCLE) molecular characterizations and extracted protein-coding gene expression measurements, resulting in 19144-length cell line feature vectors. In total, 545 total compounds or compound pairs and 860 cell lines comprised 366,710 unique pairs and 5,849,340 total individual examples of compound response at various concentrations.

ChemProbe architecture, training, and evaluation

The study focused on predicting drug sensitivity in the context of pharmacological intervention by integrating cell state features with compound features. To achieve this, we formulated a conditional model where cellular viability is predicted based on a vector of standardized protein-coding RNA abundance values and a vector of chemical features, including structure and concentration. We explored two methods of integrating gene expression and small molecule feature representations: simple concatenation and hierarchical integration using feature-wise linear modulation (FiLM).

ChemProbe includes a conditional encoder that embeds compound features into a vector of length c and an inputs encoder that embeds gene expression features into a vector of length g . We used a FiLM generator to predict γ and β parameters of length g based on compound

embeddings. The FiLM layer then applies an affine transformation of gene expression embeddings by γ and β parameters. This process repeats across n FiLM layers, and the modulated gene expression embeddings pass through a linear block consisting of a linear layer, ReLU activation, batch normalization, and dropout. The final linear block compresses feature maps to a vector of length 1, and the mean-squared error is calculated between predicted cellular viability and true cellular viability.

To evaluate the performance of our model, we used cross-validation and split cell line-compound pairs into five groups of approximately equal size by cell line to avoid data leakage and performance inflation. We trained five individual models in a leave-one-out cross-validation scenario and applied 20 rounds of hyperparameter optimization to all five individually trained models. We implemented the ChemProbe model in PyTorch and applied hyperparameter optimization with Optuna.

Predictive modeling baselines

We compared different models that modify gene expression features by compound structure and concentration using various transformations. Our baseline model, "concatenation" architecture, simply combined gene expression and compound features into a single vector, which was fed into a multi-layer perceptron. We independently evaluated the isolated effects of learning transformation types using the "scale" and "shift" variants of the ChemProbe model. The "scale" model held shift parameters constant ($\beta=0$) and learned only the scale parameters (γ), whereas the "shift" model held scale parameters constant ($\gamma=1$) and learned only the shift parameters (β). We assessed ChemProbe's dependence on compound concentration by creating a "permuted" model that used random binary fingerprints for each compound, ablating structural information. We trained and evaluated all models using 5-fold cross-validation on the originally defined dataset splits for three rounds of hyperparameter optimization.

Dose-response modeling

To generate predicted dose-response curves, log-logistic functions were fit to each set of cell line-compound predictions obtained from the five individually trained ChemProbe models. A sequence of quality control conditions was defined to ensure the reliability of each dose-response relationship. Firstly, cellular viability at any of the four largest compound

concentrations was checked for increases of 20% or more from the fifth largest compound concentration. If this condition was met, the viability prediction at the largest concentration was dropped. This process was repeated recursively, and a minimum of 16 data points was required for fitting a dose-response curve. If the minimum predicted cellular viability was greater than 0.4, no dose-response curve was fit. For cell line-compound pairs that passed quality control, a 4-parameter log-logistic function was fit. If the optimization failed, a 3-parameter log-logistic function was fit. If this optimization also failed, a 2-parameter log-logistic function was fit. Additional quality control was performed during the analysis of predicted dose-response curves by filtering out log-logistic functions with undetermined parameters and with predicted $EC_{50} < 1e-3$ or $EC_{50} > 300$. Scipy was used to fit parameters of log-logistic functions to dose-response relationships.

For relative potency comparisons, the drc package in R was employed to fit dose-response models with a four-parameter log-logistic model. We focused on the median effective dose (ED50) as an indicator of relative potency, calculating it with the EDcomp function. Significant differences in compound effects between cell lines were assessed using t-values and p-values obtained from EDcomp.

Retrospective I-SPY2 analysis

We obtained I-SPY2 clinical trial metadata and microarray characterizations of 988 patient transcriptomes from the Gene Expression Omnibus (GEO) (GSE194040). We matched 90% of the recorded genes to our training dataset, mean-imputed the remaining 10% of genes, and standardized the data using Z-score transformation. We then evaluated the alignment of I-SPY2 patient data with CCLE cell line training data across the first two principal components. Next, we predicted drug sensitivity for each patient across 32 concentrations (1E-3 uM – 300 uM) in response to all 545 compounds and compound pairs in the CTRP. We generated patient-drug response predictions using independent models and computed the area under the curve (AUC) of each predicted dose-response assay. We scaled the AUC of each patient-drug prediction between 0-1 based on the drug's minimum and maximum predicted AUC across all I-SPY2 patients.

Participants in the I-SPY2 trial were placed in treatment arms based on analyses of clinical and molecular information analyses, including clinical characteristics, gene expression

patterns measured via microarray, and protein abundance as measured by reverse phase protein array (RPPA). The trial assessed the efficacy of various combination therapies relative to paclitaxel treatment, the clinical standard of care. We identified drugs matched between I-SPY2 treatment arms and the CTRP, including paclitaxel, neratinib, MK2206, veliparib, and carboplatin. In the I-SPY2 experimental arms, patients were treated with a combination of paclitaxel and an additional drug(s) to assess response relative to paclitaxel treatment only. As the predictive ability of ChemProbe was only evaluated with respect to the available compounds and compound pairs in the CTRP, the ChemProbe predictions for I-SPY2 patients reflected predicted patient response to a single compound rather than a combination therapy.

Prospective differential potency predictions

To identify differentially potent compounds between HCC1806-Par and MDA-MB-231-Par cell lines, we computed the difference in predicted IC₅₀ values for compounds that passed dose-response modeling. We visually examined dose-response curves of the top 50 differentially sensitive compounds and selected candidates for *in vitro* testing. We based selection criteria on the completeness of dose-response curves in each cell line, including adequate E_{max} and E_{min} boundaries within the predicted concentration range.

We conducted a preliminary dose-response experiment to determine appropriate concentration points for the subsequent dose-response experiments across a broader range of concentrations than our predictions (300—1.7e-3 uM, 12 points) (Extended Data Fig 4b,c). We narrowed the concentration range for the following experiment to capture response granularity (100—2.1e-6 uM, 12 points) (Fig 4).

Feature attribution for model interpretation

Integrated gradients

We employed integrated gradients, a path-based model attribution technique, to determine the extent to which feature gradients changed compared to a baseline feature vector. The method involves linearly interpolating n feature vectors between a designated baseline and the query feature vector. We used zero-vector baselines for compound and gene expression features and set $n = 50$ as the step size. At each interpolated feature vector step, gradients of the inputs are calculated with respect to the corresponding prediction. Finally, the integral of each

feature along the path of feature gradients between the baseline vector and the query vector is computed. The python package captum was used to compute integrated gradients.

To account for potential differences in cellular responses, we used the predicted compound IC50 for each cell line-compound pair to calculate integrated gradients and obtain an attribution vector at the predicted IC50. We then extracted the cell line feature attribution vector for each pair to investigate the influence of conditional compound information on gradient changes in the input gene expression features. To address cell line-specific effects, we standardized the transcriptome attribution vectors of each cell line separately using a Z-score transformation, resulting in adjusted attribution vectors (Extended Data Fig 5b,c).

Attribution method soundness checks

To evaluate the sensitivity of the attribution method to learned parameters and data features, we conducted soundness checks. First, we assessed model-dependent attribution method invariance by comparing the attribution vectors of randomly initialized parameters of architecturally identical models with those of the trained models. We applied integrated gradients to the trained and randomly initialized models and compared the attribution vectors. Second, we evaluated data-dependent attribution method invariance by permuting the data labels, training architecturally identical models, and applying integrated gradients to compare the true-model and permuted-model attribution vectors (Extended Data Fig 5c). We used the correlation between the attribution vectors of the true and alternative models to assess the attribution method's sensitivity to learned parameters and dependence between data features and labels.

Attribution similarity analysis

We investigated the relationship between compound MOAs and learned gene expression feature dependence by examining attribution vector similarity. First, we filtered attribution vectors by considering compound MOA classes with at least two compounds successfully attributed in all seven cell lines to obtain MOA classes with sufficient samples for analysis (control compound set). This resulted in 28 MOA classes, which served as a true label baseline. We then compared these true labels to unsupervised labels generated by K-means clustering of attribution vectors from a trained model, a randomly initialized model, compound fingerprints, and a label-permutation baseline (Fig 5b). We applied K-means clustering on five independent trials.

We analyzed gene target attributions to further investigate the model dependence on individual nominal targets within each MOA class. Specifically, we applied a two-sided Wilcoxon-rank sum test to group attributions for each nominal target in the MOA class of interest and adjusted for false discovery rate (FDR) using the Benjamini-Hochberg (BH) procedure. We visualized the nominal target with the largest average attribution difference between groups for each MOA class (Fig 5c).

Attribution network analysis

We extended our analysis to include all attribution vectors generated from the 7-cell line test set. We randomly selected a single nominal target from each compound MOA class to avoid bias towards closely associated targets. This is because the nominal targets of a single compound likely fall in close network proximity, and downstream network analysis of target sets would reflect artificial over-connectivity. For example, the MOA class of neratinib includes nominal targets EGFR and HER2, which are involved in the same pathway. Therefore, we randomly chose one target from this set.

We applied Leiden clustering unsupervised discovery of attribution clusters. As described above, we defined attribution cluster MOA classes by random target selection from each compound MOA class. We filtered the STRING database to consider only high-confidence protein-protein associations (combined score > 0.7). We queried STRING for attribution cluster nominal targets and computed the connectivity of the resulting subgraph. To account for random subgraph connectivity due to target biases in STRING, we randomly sampled from available targets, queried the filtered STRING database, and computed connectivity. We repeated this procedure with randomly sampled protein-coding genes to account for random protein associations (Fig 5f). We used the networkx library for analysis.

To test for protein interaction enrichment, we defined attribution cluster nominal targets by random target selection from each compound MOA class, as described above. Next, we queried the STRING API for protein-protein interaction enrichment in the network of high-confidence protein-protein associations (combined score > 0.7). We computed statistical enrichment using the hypergeometric test, which tests if a query set of proteins has more interactions than expected relative to the background proteome-wide interaction distribution. We also applied the hypergeometric test for functional enrichment of GO terms, KEGG pathways, and Reactome pathways. We used the stringdb python package to access the STRING API. To

infer potential modules of action for compounds, we selected the unique set of all nominal targets associated with an attribution cluster.

Cell line characterization and differential expression analysis

RNA sequencing was conducted on seven test cell lines, namely HCC1806-Par, HCC1806-LMb/c, MDA-MB-231-Par, MDA-MB-231-LM2, SW480, and SW480-LvM2⁵⁵. Using RNA that was rRNA-depleted with Ribo-Zero Gold (Illumina), libraries were prepared with SciptSeq-v2 (Illumina) and sequenced on an Illumina HiSeq4000 at UCSF Center for Advanced Technologies. Transcript abundances were quantified using Salmon, and tximport was utilized to summarize transcript-level measurements. We employed DESeq2 to identify differentially expressed genes.

Differential attribution analysis

To assess model dependence on individual genes within attribution clusters, we conducted an unbiased analysis. We applied a two-sided Wilcoxon-rank sum test to each gene to analyze gene attributions within a cluster relative to all remaining samples. We adjusted for FDR using BH to account for multiple testing. We utilized scanpy to apply tests across genes in each cluster relative to all other samples. Attributions were standard scaled and each cluster's top 10 most significant genes were plotted. Leiden groups were hierarchically clustered (complete linkage) by Pearson correlation. Scanpy was used for computation and visualization. We obtained gene expression—sensitivity Pearson correlation z-scores and corresponding visualizations from the Cancer Therapeutics Response Portal v2 feature correlation analysis (Extended Data Figure 6b,c).

Dose-response assay and cell culture

MDA-MB-231-Par and HCC1806-Par cells were seeded at 1,000 cells per well in quadruplicate per condition in a white opaque 96-well plate (catalog no. 3917, Corning). Twenty-four hours later, cells were treated with serial dilutions between 2.05pM and 100uM of the following compounds: neratinib (catalog no. 18404, Cayman Chemical), CAY10618, 1S,3R-RSL-3 (catalog no. 19288, Cayman Chemical), AZD7762 (catalog no. 11491, Cayman Chemical), ceranib-2 (catalog no. 11092, Cayman Chemical), and ML162 (catalog no. 20455,

Cayman Chemical), and DMSO control. Cells were treated for 72 hours with media replaced every 24 hours. Cell viability was measured with the CellTiter-Glo 2.0 Assay (catalog no. G9243, Promega Corporation) with 1,000 ms integration time.

All cells were cultured at 37 °C in a humidified incubator with 5% CO₂. MDA-MB-231 (ATCC HTB-26) cells were grown in DMEM supplemented with 10% FCS, penicillin (100 U ml⁻¹), streptomycin (100 µg ml⁻¹) and amphotericin (1 µg ml⁻¹). HCC1806 (ATCC CRL-2335) cells were grown in Roswell Park Memorial Institute-1640 medium supplemented with 10% FCS, L-glutamine (2 mM), sodium pyruvate (1 mM), penicillin (100 U ml⁻¹), streptomycin (100 µg ml⁻¹) and amphotericin (1 µg ml⁻¹).

Acknowledgments

This work was supported by CZI grant DAF2018-191905 (DOI 10.37921/550142lkcjzw) from the Chan Zuckerberg Initiative DAF, an advised fund of Silicon Valley Community Foundation (funder DOI 10.13039/100014989) (M.J.K.), the National Institute of Mental Health of the National Institutes of Health (U01 MH115747-02 M.J.K.). We thank Zhipeng Li for his valuable insights into ferroptosis interpretation and for generously sharing the sequencing data of the LRP8 KO cell line.

Author Information

Authors and Affiliations

Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA, USA

William Connell, Michael J. Keiser

Institute for Neurodegenerative Diseases, University of California, San Francisco, San Francisco, CA, USA

William Connell, Michael J. Keiser

Bakar Computational Health Sciences Institute, University of California, San Francisco, San Francisco, CA, USA

William Connell, Kristle Garcia, Hani Goodarzi, Michael J. Keiser

Department of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, CA, USA

Kristle Garcia, Hani Goodarzi

Department of Urology, University of California, San Francisco, San Francisco, CA, USA

Kristle Garcia, Hani Goodarzi

Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA

Kristle Garcia, Hani Goodarzi

Contributions

Conceptualization, W.C.; Methodology, W.C.; Software, W.C.; Validation, K.G.; Formal analysis, W.C.; Investigation, W.C., K.G.; Data curation, W.C.; Writing - Original Draft, W.C.; Writing - Review & Editing, W.C., M.J.K.; Visualization, W.C.; Supervision, H.G., M.J.K.; Project administration, M.J.K.; Funding acquisition, H.G., M.J.K.

Corresponding authors

Correspondence to Michael J. Keiser (keiser@keiserlab.org)

Data Availability

Training and validation data from CTRP v1/2 can be downloaded at ftp://caftpd.nci.nih.gov/pub/OCG-DCC/CTD2/Broad/CTRPv2.0_2015_ctd2_ExpandedDataset/CTRPv2.0_2015_ctd2_ExpandedDataset.zip. CCLE expression data can be downloaded at <https://ndownloader.figshare.com/files/24613325>. CCLE sample metadata can be downloaded at <https://ndownloader.figshare.com/files/24613394>. I-SPY2 gene expression data is located at [GSE194040](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE194040) (GSE194040_ISPY2ResID_AgilentGeneExp_990_FrshFrzn_meanCol_geneLevel_n988.txt.gz). I-SPY2 patient-level biomarker scores, subtype classes, and clinical/response data was gathered from supplementary information of Wolf, et. al: <https://www.cell.com/cms/10.1016/j.ccell.2022.05.005/attachment/c220411b-c281-41e8-befa-a45e48af9c64/mmc3.xlsx>. HGNC was used to map gene names: <https://www.genenames.org/tools/multi-symbol-checker/>. Protein—protein interaction data was downloaded from the STRING database v11.5. The current file version is found here: <https://stringdb-downloads.org/download/protein.links.v12.0/9606.protein.links.v12.0.txt.gz>. CCLE gene expression—sensitivity Pearson correlation z-scores and corresponding

visualizations were obtained from the CTRP v1/2 web portal:

<https://portals.broadinstitute.org/ctrp.v2.1/>. RNA sequencing gene expression profiles of triple negative breast cancer cell line HCC1143 WT and LRP8 KO were obtained from a data access request to Zhipeng Li as original data from related publication⁴⁸. The enrichr web portal was used to perform Wikipathway, KEGG and GO enrichment analysis (<https://maayanlab.cloud/Enrichr/>). Source data for all tables and figures are provided with this paper.

Code Availability

Our code to download, preprocess data, reproduce model training, load pretrained weights, and run model inference is available as open source at <https://github.com/keiserlab/chemprobe>.

Tables

Model	R2
concatenation	0.6066 ± 0.0165
shift	0.7060 ± 0.0304
scale	0.7113 ± 0.0081
FiLM	0.7089 ± 0.0040
structural ablation	0.3016 ± 0.0304

Table 1 | Predictive performance.

Average performance and standard error of 5 models trained across identical data folds.

Compound	ED50 Ratio (HCC1806- Par/MDA-MB-231- Par)	t-value	p-value
neratinib	0.4946 ± 0.2426	-2.0830	4.0220e-2
ceranib-2	0.5165 ± 0.1943	-2.4887	1.4700e-2
CAY10618	0.2089 ± 1.869e-2	-42.3233	1.1593e-59
AZD7762	0.5639 ± 0.1004	-4.3430	3.7500e-5
1S,3R-RSL-3	2.1123 ± 0.4446	2.5244	1.3384e-2
ML162	3.008 ± 0.7041	2.8521	5.4120e-3

Table 2 | Relative potency at median effective dose.

Relative potency of each compound at the median effective dose (ED50) between cell lines.

Figures




Fig. 1 | ChemProbe design and model interpretation.

(a) Workflow of model training, validation, prediction, dose-response modeling, and feature attribution. We trained a deep neural network model to predict drug sensitivity at specific compound concentrations and fit log-logistic models to predictions. We derived compound pharmacodynamics from dose-response curves and applied integrated gradients saliency mapping to predicted IC₅₀ to derive input feature attributions. IC₅₀, inhibitory concentration of compound at 50% cellular viability. (b) Architecture of the conditional neural network (ChemProbe) trained to predict cell line viability from molecular features and compound structure. ChemProbe learns an embedding of protein-coding gene expression features conditioned by parameters learned from an embedding of compound structure and concentration.

(c) Decomposition of learned conditioning parameters. Points represent compound-concentration samples; color indicates compound; size indicates concentration; and shape indicates parameter.




Fig. 2 | I-SPY2 clinical trial retrospective analysis.

(a) Predicted dose-response AUC for I-SPY2 patients treated with each drug. AUCs scaled between the minimum and maximum predicted AUC of patients treated with each drug. Blue =

non-responder, orange = responder; center line, median; box limits, upper and lower quartiles; whiskers, 1.5x interquartile range; points, outliers; two-sided Wilcoxon rank-sum test; ns: $p \leq 1e1$, $*p \leq 5e-2$, $**p \leq 1e-2$. (b) Receiver operating characteristic curve of patients treated with each drug and corresponding auROC. (c) Accuracy of I-SPY2 predictions versus ChemProbe predictions for non-responders/responders. Center line, median; box limits, upper and lower quartiles; whiskers, 1.5x interquartile range; points, outliers); two-sided Wilcoxon rank-sum test; $*p \leq 5e-2$.




Fig. 3 | Differential potency and *in silico* dose-response curve predictions.

(a) Approach to model training and dose-response modeling. We trained individual models on held-out cell line dataset splits by 5-fold cross-validation. We then fit log-logistic models to cross-validated model predictions and derived pharmacodynamic features. (b) Expected cumulative distribution plot of predicted compound IC₅₀ differences between HCC1806 and MDAMB231 cell lines. Compounds selected for *in vitro* dose-response testing highlighted. (c)

Predicted dose-response relationships of HCC1806 and MDAMB231 response to neratinib and (d) 1S,3R-RSL-3. 95% confidence intervals.




Fig. 4 | Validation of differential potency predictions.

(a-d) In vitro dose-response relationships of HCC1806-Par differentially potent compounds and (e-f) MDA-MB-231-Par differentially potent compounds. 95% confidence intervals. (g)

Relationship between the predicted and observed differences in IC50 values of tested compounds between HCC1806-Par and MDA-MB-231-Par cell lines. Two-sided t-test.




Fig. 5 | Feature attribution analysis of nominal compound targets.

(a) Distinct protein target clusters emerge from UMAP decomposition of adjusted attribution vectors at compound IC50s for predicted and fitted dose-response relationships in MDAMB231, MDAMB231-LM2, HCC1806, HCC1806-LM2b/c, SW480, and SW480-LvM2 prospective cell lines. Control compound set (CCS) attribution vectors colored by nominal target class. (b)

Comparison of adjusted mutual information (AMI) derived from CCS nominal target labels and K-means clustering of trained model adjusted attribution vectors, compound fingerprints, random model adjusted attribution vectors and permuted model adjusted attribution vectors. Center line, median; box limits, upper and lower quartiles; whiskers, 1.5x interquartile range; points, outliers; two-sided Wilcoxon rank-sum test; $*p \leq 5e-2$, $**p \leq 1e-2$. (c) Average attribution difference between the highest significance target of the nominal target class versus all other target classes. Two-sided Wilcoxon rank-sum test; $*p \leq 5e-2$, $**p \leq 1e-2$, $***p \leq 1e-3$, $****p \leq 1e-4$. (d) Leiden clustering of all attribution vectors. (e) Comparison of PPI subgraph connectivity derived from clustered target profiles, random target profiles, and random protein-coding genes. Center line, median; box limits, upper and lower quartiles; whiskers, 1.5x interquartile range; points, outliers; two-sided Wilcoxon rank-sum test; $***p \leq 1e-3$, $****p \leq 1e-4$. (f) Network representation of select clustered target profile subgraphs.





Fig. 6 | Differential attribution analysis (DAA) of ferroptosis-inducing compounds.

(a) Heatmap of top-10 differentially attributed genes within Leiden clusters from Fig 5d. Clusters ordered by hierarchical clustering of DAA profiles (columns). Rows: top-10 attributed genes, columns: cell line-compound attribution sample. (b) Comparison of predicted IC_{50} s between cluster 26 (ferroptosis-sensitive) and cluster 28 (ferroptosis-resistant). Center line, median; box limits, upper and lower quartiles; whiskers, 1.5x interquartile range; points, outliers; two-sided Wilcoxon rank-sum test; * $p \leq 5e-2$. (c) Volcano plot of DAA results derived by comparing


ferroptosis-inducing compound attributions to all other compound attributions. Known ferroptosis-mediating genes in orange. (d) Expected cumulative distribution plot of predicted compound IC₅₀ differences between HCC1143 WT and LRP8 KO cell lines. Ferroptosis-inducing compounds predicted differentially potent in LRP8 KO marked. (e) Enrichment analysis of top-10 differentially attributed genes of ferroptosis-inducing compound samples. Fisher's exact test.

Extended Data Figures




Extended Data Fig. 1 | Conditional parameter analysis.

(a) Hierarchical clustering of learned gamma parameters. Color bars indicated compound identity and squared compound concentration. (b) Relationship between principal component 1 (PC1) of learned beta parameters and input concentration; Pearson correlation coefficient.




Extended Data Fig. 2 | I-SPY2 analysis.

(a) I-SPY2 participant tumor gene expression profiles projected on the CCLE training data distribution. VC, veliparib/carboplatin; N, neratinib; Ctr, control; gray = kernel density estimate (KDE) of training data distribution. (b) I-SPY2 confusion matrix of predicted response and observed response. (c) ChemProbe confusion matrix of predicted response and observed response.



Extended Data Fig. 3 | Prospective cell line expression similarity analysis.


(a) PCA of gene expression similarity between prospectively tested cell lines and matched counterparts in the CTRP training data. gray = KDE of training data distribution.



Extended Data Fig. 4 | Prospective dose-response analysis.


(a) Relationship between predicted and observed IC₅₀s of prospectively tested compounds in HCC1806-Par and MDA-MB-231-Par cell lines. Two-sided t-test. (b) Calibration experiment; relationship between predicted difference in IC₅₀ and observed difference in IC₅₀ between HCC1806-Par and MDA-MB-213-Par across tested compounds. Two-sided t-test. (c) Calibration

experiment; relationship between predicted and observed IC50s of prospectively tested compounds in HCC1806-Par and MDA-MB-231-Par cell lines. Two-sided t-test.



Extended Data Fig. 5 | Attribution analysis.

PCA decompositions of (a) raw attribution vectors versus (b) adjusted attribution vectors. (c) Pearson correlation between raw attributions and adjusted attributions versus transcriptome inputs, randomly initialized model attributions, and attributions of a model trained on permuted labels. (d-g) UMAP of cell line-compound attribution samples colored by compound targets with specific attributions. (h-k) UMAP of cell line-compound attribution samples colored by compound targets with diffuse attributions.



Extended Data Fig. 6 | Ferroptosis analysis.

(a) DEA between MDA-MB-231-Par and HCC1806-Par with ferroptosis-associated genes in orange. (b) Pearson correlation z-score between highly-attributed LONRF3 expression and compound sensitivity. (c) Pearson correlation z-score between highly-attributed SLC27A5 expression and compound sensitivity. (d) Differential attribution scores of top 10 genes from ferroptosis-sensitive cell line-compound pairs relative to all others.

References

1. Arrowsmith, C. H. *et al.* The promise and peril of chemical probes. *Nat. Chem. Biol.* **11**, 536–541 (2015).
2. Workman, P. & Collins, I. Probing the probes: fitness factors for small molecule tools. *Chem. Biol.* **17**, 561–577 (2010).
3. Blagg, J. & Workman, P. Choose and Use Your Chemical Probe Wisely to Explore Cancer Biology. *Cancer Cell* **32**, 9–25 (2017).
4. Roden, D. M. *et al.* Pharmacogenomics. *Lancet* **394**, 521–532 (2019).
5. Tyner, J. W. *et al.* Understanding Drug Sensitivity and Tackling Resistance in Cancer. *Cancer Res.* **82**, 1448–1460 (2022).
6. Baptista, D., Ferreira, P. G. & Rocha, M. Deep learning for drug response prediction in cancer. *Brief. Bioinform.* **22**, 360–379 (2021).
7. Costello, J. C. *et al.* A community effort to assess and improve drug sensitivity prediction algorithms. *Nat. Biotechnol.* **32**, 1202–1212 (2014).
8. Partin, A. *et al.* Deep learning methods for drug response prediction in cancer: Predominant and emerging trends. *Front. Med.* **10**, 1086097 (2023).
9. Menden, M. P. *et al.* Machine learning prediction of cancer cell sensitivity to drugs based on genomic and chemical properties. *PLoS One* **8**, e61318 (2013).
10. Chiu, Y.-C. *et al.* Predicting drug response of tumors from integrated genomic profiles by deep neural networks. *BMC Med. Genomics* **12**, 18 (2019).
11. Sharifi-Noghabi, H., Zolotareva, O., Collins, C. C. & Ester, M. MOLI: multi-omics late integration with deep neural networks for drug response prediction. *Bioinformatics* **35**, i501–i509 (2019).
12. Ding, M. Q., Chen, L., Cooper, G. F., Young, J. D. & Lu, X. Precision Oncology beyond Targeted Therapy: Combining Omics Data with Machine Learning Matches the Majority of Cancer Cells to Effective Therapeutics. *Mol. Cancer Res.* **16**, 269–278 (2018).

13. Rampasek, L., Hidru, D., Smirnov, P., Haibe-Kains, B. & Goldenberg, A. Dr.VAE: Drug Response Variational Autoencoder. *arXiv [stat.ML]* (2017).
14. Li, M. *et al.* DeepDSC: A Deep Learning Method to Predict Drug Sensitivity of Cancer Cell Lines. *IEEE/ACM Trans. Comput. Biol. Bioinform.* **18**, 575–582 (2021).
15. Chen, J. *et al.* Deep transfer learning of cancer drug responses by integrating bulk and single-cell RNA-seq data. *Nat. Commun.* **13**, 6494 (2022).
16. Liu, Q., Hu, Z., Jiang, R. & Zhou, M. DeepCDR: a hybrid graph convolutional network for predicting cancer drug response. *Bioinformatics* **36**, i911–i918 (2020).
17. Yi, H.-C., You, Z.-H., Huang, D.-S. & Kwoh, C. K. Graph representation learning in bioinformatics: trends, methods and applications. *Brief. Bioinform.* **23**, (2022).
18. Zuo, Z. *et al.* SWnet: a deep learning model for drug response prediction from cancer genomic signatures and compound chemical structures. *BMC Bioinformatics* **22**, 434 (2021).
19. Manica, M. *et al.* Toward Explainable Anticancer Compound Sensitivity Prediction via Multimodal Attention-Based Convolutional Encoders. *Mol. Pharm.* **16**, 4797–4806 (2019).
20. Chang, Y. *et al.* Cancer Drug Response Profile scan (CDRscan): A Deep Learning Model That Predicts Drug Effectiveness from Cancer Genomic Signature. *Sci. Rep.* **8**, 8857 (2018).
21. Janizek, J. D. *et al.* Uncovering expression signatures of synergistic drug responses via ensembles of explainable machine-learning models. *Nat Biomed Eng* (2023) doi:10.1038/s41551-023-01034-0.
22. Cadow, J., Born, J., Manica, M., Oskooei, A. & Rodríguez Martínez, M. PaccMann: a web service for interpretable anticancer compound sensitivity prediction. *Nucleic Acids Res.* **48**, W502–W508 (2020).
23. Parca, L. *et al.* Modeling cancer drug response through drug-specific informative genes. *Sci. Rep.* **9**, 15222 (2019).
24. Zhang, H., Chen, Y. & Li, F. Predicting Anticancer Drug Response With Deep Learning Constrained by Signaling Pathways. *Frontiers in Bioinformatics* **1**, 10 (2021).
25. Kuenzi, B. M. *et al.* Predicting Drug Response and Synergy Using a Deep Learning Model of

- Human Cancer Cells. *Cancer Cell* **38**, 672–684.e6 (2020).
26. Rees, M. G. *et al.* Correlating chemical sensitivity and basal gene expression reveals mechanism of action. *Nat. Chem. Biol.* **12**, 109–116 (2016).
27. Ghandi, M. *et al.* Next-generation characterization of the Cancer Cell Line Encyclopedia. *Nature* **569**, 503–508 (2019).
28. Perez, E., Strub, F., De Vries, H. & Dumoulin, V. Film: Visual reasoning with a general conditioning layer. *arXiv preprint arXiv* (2017).
29. Chuang, K. V. & Keiser, M. J. Comment on ‘Predicting reaction performance in C–N cross-coupling using machine learning’. *Science* **362**, eaat8603 (2018).
30. Chuang, K. V. & Keiser, M. J. Adversarial Controls for Scientific Machine Learning. *ACS Chem. Biol.* **13**, 2819–2821 (2018).
31. Nanda, R. *et al.* Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial. *JAMA Oncol* **6**, 676–684 (2020).
32. Wolf, D. M. *et al.* Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies. *Cancer Cell* **40**, 609–623.e6 (2022).
33. Mantione, K. J. *et al.* Comparing bioinformatic gene expression profiling methods: microarray and RNA-Seq. *Med. Sci. Monit. Basic Res.* **20**, 138–142 (2014).
34. Ahmadian, M. *et al.* Analysis of the FHIT gene and FRA3B region in sporadic breast cancer, preneoplastic lesions, and familial breast cancer probands. *Cancer Res.* **57**, 3664–3668 (1997).
35. Gazdar, A. F. *et al.* Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer. *Int. J. Cancer* **78**, 766–774 (1998).
36. Brinkley, B. R. *et al.* Variations in cell form and cytoskeleton in human breast carcinoma cells in vitro. *Cancer Res.* **40**, 3118–3129 (1980).
37. Cailleau, R., Olivé, M. & Cruciger, Q. V. Long-term human breast carcinoma cell lines of metastatic origin: preliminary characterization. *In Vitro* **14**, 911–915 (1978).

38. Liu, Y. *et al.* Multi-omic measurements of heterogeneity in HeLa cells across laboratories. *Nat. Biotechnol.* **37**, 314–322 (2019).
39. Minn, A. J. *et al.* Genes that mediate breast cancer metastasis to lung. *Nature* **436**, 518–524 (2005).
40. Earnest-Noble, L. B. *et al.* Two isoleucyl tRNAs that decode synonymous codons divergently regulate breast cancer metastatic growth by controlling translation of proliferation-regulating genes. *Nat Cancer* **3**, 1484–1497 (2022).
41. Loo, J. M. *et al.* Extracellular metabolic energetics can promote cancer progression. *Cell* **160**, 393–406 (2015).
42. Gupta, A. & Arora, S. A Simple Saliency Method That Passes the Sanity Checks. *arXiv [cs.LG]* (2019).
43. Adebayo, J. *et al.* Sanity Checks for Saliency Maps. *arXiv [cs.CV]* (2018).
44. Maggiora, G., Vogt, M., Stumpfe, D. & Bajorath, J. Molecular similarity in medicinal chemistry. *J. Med. Chem.* **57**, 3186–3204 (2014).
45. Szklarczyk, D. *et al.* STRING v10: protein-protein interaction networks, integrated over the tree of life. *Nucleic Acids Res.* **43**, D447–52 (2015).
46. Stockwell, B. R. Ferroptosis turns 10: Emerging mechanisms, physiological functions, and therapeutic applications. *Cell* **185**, 2401–2421 (2022).
47. Li, J. *et al.* Ferroptosis: past, present and future. *Cell Death Dis.* **11**, 88 (2020).
48. Li, Z. *et al.* Ribosome stalling during selenoprotein translation exposes a ferroptosis vulnerability. *Nat. Chem. Biol.* 1–11 (2022).
49. Duffy, M. J. & Crown, J. A personalized approach to cancer treatment: how biomarkers can help. *Clin. Chem.* **54**, 1770–1779 (2008).
50. Tsimberidou, A. M., Fountzilas, E., Nikanjam, M. & Kurzrock, R. Review of precision cancer medicine: Evolution of the treatment paradigm. *Cancer Treat. Rev.* **86**, 102019 (2020).
51. Alipanahi, B., Delong, A., Weirauch, M. T. & Frey, B. J. Predicting the sequence specificities of DNA- and RNA-binding proteins by deep learning. *Nat. Biotechnol.* **33**, 831–838 (2015).

52. Avsec, Ž. *et al.* Base-resolution models of transcription-factor binding reveal soft motif syntax. *Nat. Genet.* **53**, 354–366 (2021).
53. Jumper, J. *et al.* Highly accurate protein structure prediction with AlphaFold. *Nature* (2021)
doi:10.1038/s41586-021-03819-2.
54. Rives, A. *et al.* Biological structure and function emerge from scaling unsupervised learning to 250 million protein sequences. *Proc. Natl. Acad. Sci. U. S. A.* **118**, (2021).
55. Culbertson, B. *et al.* A sense-antisense RNA interaction promotes breast cancer metastasis via regulation of NQO1 expression. *Nat Cancer* **4**, 682–698 (2023).